/DVAX

DVAX Stock - Dynavax Technologies Corporation

Q: What is the analyst price target for DVAX?

Analyst price target information is not currently available for DVAX.

Q: What is DVAX's market cap?

Market capitalization information is not currently available for DVAX.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$15.72+0.26%

+$0.04 (+0.26%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+100.4%upside

Target: $31.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for DVAX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.89

52W High$15.73

52W Low$9.20

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$277.25M	$232.28M	$722.68M	$439.44M	$46.55M
Gross Profit	$227.80M	$182.12M	$460.53M	$265.87M	$32.64M
Gross Margin	82.2%	78.4%	63.7%	60.5%	70.1%
Operating Income	$-4,122,000	$-37,028,000	$283.52M	$134.49M	$-75,222,000
Net Income	$27.31M	$-6,389,000	$293.16M	$76.71M	$-75,240,000
Net Margin	9.9%	-2.8%	40.6%	17.5%	-161.6%
EPS	$0.21	$-0.05	$2.32	$0.62	$-0.75

Company Overview

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Visit Website

Earnings History & Surprises

DVAX

Beat Rate

67%

Last 18 quarters

Avg Surprise

+56.7%

EPS vs Estimate

Beats / Misses

12/5

1 met exactly

Latest EPS

$0.21

Q4 2025

EPS Surprise History

Q1 24

+100.0%

$0.00vs$0.00

Q2 24

-40.0%

$-0.07vs$-0.05

Q3 24

+33.3%

$0.08vs$0.06

Q4 24

+9.1%

$0.12vs$0.11

Q1 25

0.0%

$0.05vs$0.05

Q2 25

-466.7%

$-0.11vs$0.03

Q3 25

+16.7%

$0.14vs$0.12

Q4 25

+50.0%

$0.21vs$0.14

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 19, 2026	$0.08	—	—	—
Q4 2025	Nov 5, 2025	$0.14	$0.21	+50.0%	✓ BEAT
Q3 2025	Aug 7, 2025	$0.12	$0.14	+16.7%	✓ BEAT
Q2 2025	May 6, 2025	$0.03	$-0.11	-466.7%	✗ MISS
Q1 2025	Feb 20, 2025	$0.05	$0.05	0.0%	= MET
Q4 2024	Nov 7, 2024	$0.11	$0.12	+9.1%	✓ BEAT
Q3 2024	Aug 6, 2024	$0.06	$0.08	+33.3%	✓ BEAT
Q2 2024	May 8, 2024	$-0.05	$-0.07	-40.0%	✗ MISS
Q1 2024	Feb 22, 2024	$0.00	$0.00	+100.0%	✓ BEAT
Q4 2023	Nov 2, 2023	$0.01	$0.10	+766.6%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.09	$0.03	+133.3%	✓ BEAT
Q2 2023	May 2, 2023	$-0.12	$-0.19	-58.3%	✗ MISS
Q1 2023	Feb 23, 2023	$0.43	$0.45	+4.7%	✓ BEAT
Q4 2022	Nov 3, 2022	$0.33	$0.43	+30.3%	✓ BEAT
Q3 2022	Aug 4, 2022	$0.22	$0.87	+295.5%	✓ BEAT
Q2 2022	May 5, 2022	$0.24	$0.22	-8.3%	✗ MISS
Q1 2022	Feb 28, 2022	$0.69	$0.55	-20.3%	✗ MISS
Q4 2021	Nov 4, 2021	$0.05	$0.06	+20.0%	✓ BEAT
Q3 2021	Aug 4, 2021	$0.01	$0.02	+155.1%	✓ BEAT

Frequently Asked Questions about DVAX

What is DVAX's current stock price?

Dynavax Technologies Corporation (DVAX) is currently trading at $15.72 per share. The stock has moved +0.26% today.

What is the analyst price target for DVAX?

The average analyst price target for DVAX is $31.50, based on 1 analyst.

What sector is Dynavax Technologies Corporation in?

Dynavax Technologies Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is DVAX's market cap?

Dynavax Technologies Corporation has a market capitalization of $1.85 billion, making it a small-cap company.

Does DVAX pay dividends?

No, Dynavax Technologies Corporation does not currently pay a dividend to shareholders.